The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation for plozasiran, Arrowhead Pharmaceuticals’ siRNA therapy targeting apolipoprotein C-III, as an adjunct to diet for adult patients with familial chylomicronemia syndrome. The European Commission is expected to issue a formal decision in the second quarter of 2026. If confirmed, plozasiran would become the first siRNA medicine authorised in the EU for FCS patients diagnosed either genetically or clinically, a distinction that carries significant weight in a disease where diagnostic confirmation has historically limited treatment access.
Why the diagnostic scope matters more than the approval headline
The CHMP opinion’s most consequential element is not the approval recommendation itself but the patient population it covers. Existing authorised medicines for FCS in Europe require genetic confirmation of the condition. Plozasiran’s label, as recommended, does not. This is not a minor regulatory concession. FCS is a condition defined by its rarity and its underdiagnosis, with estimates placing global prevalence at between one and 13 people per million. In practice, that range reflects the difficulty of confirming the diagnosis through genetic testing, not the true burden of the disease. Clinicians have long encountered patients with the FCS phenotype, including extremely elevated triglycerides and recurrent pancreatitis, who cannot be confirmed genetically, whether because of incomplete testing infrastructure, variant classification uncertainty, or heterogeneous genetic architecture. By covering clinically diagnosed patients, the CHMP opinion effectively expands the eligible population beyond what prior regulatory frameworks permitted, and the EMA explicitly acknowledged this rationale in its own statement accompanying the opinion.
Whether this translates to meaningful patient reach depends on how tightly payers in individual EU member states interpret eligibility criteria at the reimbursement stage. A positive CHMP opinion establishes the scientific and safety foundation for authorisation; it does not determine access. Health technology assessment bodies across Europe, each operating under distinct evidentiary and cost-effectiveness frameworks, will assess plozasiran against the clinical evidence and against the existing treatment landscape. For an ultra-rare disease with a small trial population, those assessments carry inherent uncertainty. The Phase 3 PALISADE study enrolled 75 subjects across 39 sites in 18 countries, a sample size that reflects the biological rarity of the condition but will draw scrutiny from HTA bodies accustomed to larger evidence bases.
What the PALISADE data actually demonstrate
The PALISADE study met its primary endpoint, a statistically significant reduction in fasting triglycerides versus placebo at month 10, and cleared all multiplicity-controlled key secondary endpoints. At the 25 mg dose, plozasiran reduced triglycerides by a median of 80% from baseline against a 17% reduction with placebo. More clinically significant for regulators and treating physicians is the secondary outcome on acute pancreatitis incidence: significantly fewer cases were observed in the plozasiran arm compared with placebo. Pancreatitis prevention is the central clinical concern in FCS management. Unlike triglyceride reduction, which is a surrogate marker, pancreatitis events are a hard clinical outcome with direct bearing on hospitalisation, mortality risk, and long-term quality of life.
The trial design, a randomised, double-blind, placebo-controlled structure, is methodologically sound, and the simultaneous publication in the New England Journal of Medicine and Circulation reflects peer review credibility. However, the small enrolled population means that the pancreatitis reduction data, while directionally compelling, carries wider confidence intervals than would be expected in a larger trial. Regulatory watchers note that for rare disease indications, the CHMP and FDA have historically tolerated smaller evidence packages when the disease burden is severe and alternative options are limited. That tolerance is embedded in the orphan designation framework plozasiran holds in both the EU and the US, and it is visible in the CHMP’s decision. The question regulators will continue to monitor is durability. The extension phase of PALISADE, where all participants received plozasiran after the randomised period, will generate longer-term data on sustained triglyceride control and ongoing pancreatitis prevention, and those data will matter for label updates and post-marketing commitments.
The mechanism and what differentiates plozasiran from prior apoC-III approaches
Plozasiran operates through RNA interference, targeting the mRNA encoding apolipoprotein C-III and preventing its production in liver cells. ApoC-III inhibits both lipoprotein lipase-mediated triglyceride hydrolysis and receptor-based clearance of triglyceride-rich lipoproteins. Silencing apoC-III production at the mRNA level achieves durable suppression rather than protein-level inhibition, and the effect persists long enough to permit quarterly subcutaneous dosing, a meaningful practical advantage over more frequent dosing regimens.
Volanesorsen, an antisense oligonucleotide targeting apoC-III that received conditional authorisation in Europe for FCS in 2019, established proof of concept for apoC-III suppression in this indication. However, volanesorsen’s safety profile included clinically significant thrombocytopenia in a subset of patients, which restricted its use and contributed to the conditional nature of its authorisation. Plozasiran uses a different molecular modality and a different hepatic delivery mechanism through Arrowhead’s TRiM platform, and the safety data from PALISADE show a different adverse event profile. The most common reactions were hyperglycaemia at 12.8%, headache at 6.8%, nausea at 4.7%, and injection site reaction at 4.7%. The absence of significant platelet-related toxicity in the PALISADE dataset distinguishes plozasiran from the prior standard, and industry observers suggest this distinction will factor into physician prescribing decisions and payer assessments across European markets.
What this signals for siRNA’s broader regulatory trajectory in Europe
The CHMP recommendation for plozasiran arrives as RNA interference therapeutics continue to expand their regulatory footprint globally. Inclisiran, a siRNA targeting PCSK9 for LDL reduction, is already authorised in Europe. Givosiran, lumasiran, and vutrisiran have followed in rare metabolic and neurodegenerative indications. Each successive approval refines the regulatory community’s understanding of the class, from delivery mechanisms and organ targeting to long-term safety monitoring and durability expectations. Plozasiran adds a new organ system dimension via its use in triglyceride biology and its hepatic targeting through the TRiM platform, while also expanding the geographic scope of regulatory confidence in subcutaneous siRNA administration.
For Arrowhead, the CHMP opinion is strategically significant beyond FCS. The company’s pipeline includes plozasiran in Phase 3 trials across severe hypertriglyceridemia and mixed dyslipidaemia indications under the SHASTA and MUIR programmes, and the US FDA granted Breakthrough Therapy designation for severe hypertriglyceridemia in December 2025. A European marketing authorisation for FCS creates a regulatory foundation and a commercial infrastructure that could support label extension applications in broader lipid-lowering indications if the ongoing trials deliver. The commercial case for those larger indications is substantially more significant than FCS alone, which serves a defined rare disease population. How regulators, payers, and cardiovascular guideline bodies eventually position plozasiran relative to statins, fibrates, and PCSK9 inhibitors in the hypertriglyceridaemia space will depend on evidence from those later trials, not on the FCS authorisation. But the European pathway is now open, and for a platform-stage company building a lipid-focused franchise, that matters.
The EC decision is expected within the second quarter of 2026. Until that decision is issued, the CHMP opinion, while historically predictive of approval, remains a recommendation rather than an authorisation. Market access negotiations in individual member states will begin in earnest only after formal approval is confirmed.
